Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC

This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy us

Trial Details

NCT ID

NCT06878274

Phase

PHASE2

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Post-operative radiotherapy

Locations (sample)

• Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

• Participants must be ≥ 18 years old
• Ability to provide written informed consent
• ECOG performance status 0-2
• Histologically confirmed NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →